The company's board of directors in a meeting held on September 7, 2020, has approved the raising of funds by the issuance and allotment of equity shares for up to an aggregate amount of up to Rs 350 crore

Dr Reddy informed the bourses on Monday that it has launched Fulvestrant injection, 250 mg/5 ml (50 mg/ml) per single-dose syringe, a therapeutic equivalent generic version of Faslodex (fulvestrant) injection, 250 mg/5 ml (50 mg/ml), approved by United States Food & Drug Administration (USFDA)

Gross premiums written in Q1FY21 stood at Rs 15881.55 crore, which declined by 23.69 per cent YoY from Rs 20813.12 crore in Q1FY20.

The floor price of the offer shall be Rs 330 per share, which is at 14 per cent discount from its previous close of Rs 384.50. This offer for sale will be open for retail investors from September 09, 2020.

Ashoka Buildcon Limited has emerged as the lowest bidder (L1) for the two projects undertaken by National Highways Authority of India (NHAI) in the state of Bihar.

The region of 11,373-11,452 is likely to act as a stiff resistance zone for the index as it is a confluence of 21-day EMA and the trendline resistance on 60-mins, which is formed by connecting lows of August 14 and 31. Stocks in news: Wipro, Dr Reddy’s Laboratories, Dhanuka Agritech.

Asian peers are buoyant in early deals on Tuesday and this optimism is sure to spill on to the Indian shores as well. SGX Nifty, which is currently trading almost with a gain of 10 points at 11,392 levels, is already reflecting it.

The company reported consolidated net sales of Rs 285 crore in Q1FY21, which declined by 10.85 per cent YoY from Rs 319.7 crore in Q1FY20.

Support is defined as a price level that may prompt a net increase in buying activity.

The consolidated net sales reported in Q1FY21 came in at Rs 435.60 crore, which declined by 30.83 per cent YoY from Rs 629.74 crore in Q1FY20.